• Gladys

  Participated · Seed · Oct 2025

  Gladys offers an AI-supported marketplace that directly connects people seeking home care with vetted local carers, eliminating traditional agency intermediaries. Its technology automates matching, scheduling, and back-office logistics, which reduces client costs and enables carers to earn up to 65% more than standard agency rates. Since launch, the platform has delivered care across a 20,000 km catchment area and facilitated tens of thousands of hours of independent living support. Co-founded by Georgina Robinson and Alex Sorisi, the company emphasizes fair pay, career development tools for carers, and high-quality support for clients. With fresh seed funding, Gladys plans a nationwide rollout, deployment of additional AI back-office agents, and investment in local care communities. The team aims to provide hundreds of thousands of hours of support by the end of 2026, positioning the business for rapid scale across the UK.

• OSSTEC

  Participated · Seed · Apr 2023

  OSSTEC is a London-based Imperial College London spinout developing 3D-printed joint replacement implants. Its first product is a cementless, less invasive partial knee implant that mimics the structure of cartilage and bone-fixing elements to stimulate bone growth. The design aims to overcome common challenges of traditional knee replacements and reduce the risk of implant failure. By leveraging 3D printing, OSSTEC says it simplifies the supply chain, improves manufacturing efficiency and could reduce costs for healthcare systems. The company plans to use newly raised funds to accelerate the launch of its technology, scale operations and engage strategic partners in the medical field. Leadership highlights clinical and workflow advantages of cementless partial knee replacement and the potential for improved fixation, survival and outcomes for patients and surgeons. OSSTEC builds porous, 3D‑printed titanium implant structures designed to emulate natural bone behaviour and stimulate bone in‑growth rather than relying on cement fixation. The technology originates from research in Imperial College London’s Department of Mechanical Engineering and includes a software platform to drive 3D printing of the structures. Animal data reportedly show improved healing and bone in‑growth versus conventional implants, and the company has human cadaveric data supporting translation to people. OSSTEC is preparing prototypes for regulatory testing and the first clinical studies, working to ensure implants can withstand expected loads and stresses. Management emphasizes engagement with surgeons to validate clinical needs and drive adoption. The company has received prior support including an Innovate UK grant in 2022 and contributions from Imperial College’s enterprise funders.

No current team members are available.